Egypt Pharmaceutical Manufacturing Market Size, Share, Growth and Forecast, 2025-2035

Local plants now supply most of the medicines Egyptians use

The Egypt pharmaceutical manufacturing market was valued at USD 4.99 billion in 2025 and is projected to increase from USD 5.42 billion in 2026 to USD 10.76 billion by 2035, registering a CAGR of 7.92% during 2026–2035. Output serves one of Africa's largest medicine markets, where generic tablets for diabetes, hypertension and infections dominate pharmacy shelves and state hospitals buy through central tenders. Greater Cairo and Giza held the largest regional share, 46.0% in 2025, because 6th of October City, Obour and the Giza plants of the leading generic makers sit close to the main wholesalers. Upper Egypt and other industrial zones form the fastest-growing region at 8.8% a year, as new active ingredient, vaccine and intravenous fluid plants open in the Suez Canal Economic Zone. Regulatory recognition has also changed the export case, since the national drug regulator now holds the World Health Organization's maturity level 3 for both medicines and vaccines.

Factory output for home and export markets is counted once

The estimate covers the value of finished human medicines made in Egypt, at ex-factory prices, whether sold to local wholesalers and pharmacies, supplied to public procurement bodies and hospitals or shipped abroad. It includes products of Egyptian private firms, state-owned producers and the local plants of multinational companies, as well as toll and contract production made for license holders.

The estimate excludes imported finished medicines, veterinary drugs, cosmetics and medical devices, and it counts active ingredients only when they are sold as part of a finished product. The value chain runs from imported and local raw materials through licensed factories and national distributors to pharmacies, hospitals and foreign buyers.

Generics lead while biologics and biosimilars grow fastest

Why do generic medicines carry most factory value?

Based on product type, the market is categorized into generic pharmaceuticals, originator and licensed brands, biologics and biosimilars, and OTC and consumer health pharmaceuticals. Generic Pharmaceuticals led with a 58.0% share of 2025 value, because the 179 licensed drug factories turn out about 3.7 billion to 4 billion dosage units a year, mostly copies of off-patent molecules, EnterpriseAM reported in November 2025. Biologics and Biosimilars grow fastest at 10.9% a year, as the African Development Bank approved a EUR 15 million loan in March 2025 to lift Minapharm's capacity from 3 million to 7.65 million doses by 2032. Locally made biosimilars can then replace costly imported antibodies in hospital tenders.

How much output still comes from tablets and capsules?

Based on dosage form, the market is categorized into solid oral dosage, parenteral products, liquid oral products and topical and inhalation products. Solid Oral Dosage led with a 62.0% share of 2025 value, because tablets and capsules are the cheapest form to make and ship, and the state-backed Gypto Pharma medicine city in Khanka built its first phase on 120,000 square meters around solid, semi-solid, liquid and sterile lines. Parenteral Products grow fastest at 9.1% a year, as Ateco Pharma's USD 10 million second phase in Ain Sokhna, opened in April 2026, raised its intravenous solution capacity to 50 million bottles a year.

Which treatment areas absorb the most factory capacity?

Based on therapeutic area, the market is categorized into cardiometabolic, anti-infectives, oncology and hematology, and CNS and respiratory. Cardiometabolic led with a 34.0% share of 2025 value, because about 13.2 million adults aged 20 to 79 lived with diabetes in 2024, an age-standardized prevalence of 22.4%, according to the IDF Diabetes Atlas, and most need lifelong daily tablets. Oncology and Hematology grows fastest at 9.8% a year, as Sandoz agreed in March 2025 to transfer full manufacturing technology for five cancer medicines to SEDICO, products with a USD 10.7 million import bill, the drug authority says.

Why do retail pharmacies take most factory shipments?

Based on customer type, the market is categorized into retail pharmacy supply, government procurement agencies, private hospitals and clinics, and export buyers. Retail Pharmacy Supply led with a 60.0% share of 2025 value, because most patients still pay out of pocket at private pharmacies, and the 57 million people covered by public insurance report shortages in state hospitals that send many of them to pharmacy counters, Al Majalla reported in December 2025. Export Buyers grow fastest at 9.6% a year, as first-quarter 2026 drug exports reached USD 280 million, up 7% on the year, Business Monthly reported.

State pricing rules favor locally made medicines

Prices for registered medicines are set by the drug authority rather than by the market, so factory margins depend on how quickly approved prices follow costs. A new formula took effect on Sept. 24, 2026, weighting the exchange rate at 60%, urban inflation at 30% and the central bank deposit rate at 10%, according to EnterpriseAM. Drugmakers were reported in November 2026 to be seeking a 20% increase, while analysts estimated the formula supports about half of that. The rules also price local products well below imports, which gives Egyptian plants a lasting cost edge in pharmacies and tenders.

Localization, chronic care and WHO recognition drive output

How does deepening localization move value to local plants?

Import substitution is the largest single source of new factory volume, because every localized product moves value from foreign suppliers to Egyptian lines. The drug authority says 155 active ingredients were localized in 2023 to 2025 for use in 234 finished products, replacing imports worth about USD 691 million, Business Monthly reported in August 2026. EnterpriseAM counted 208 localized medicines whose import bill had exceeded USD 732 million a year. The Chamber of Pharmaceutical Industry also told Asharq Business in May 2025 that producers would invest about EGP 4 billion that year in 20 new production lines. For suppliers of equipment, excipients and packaging, this means a steady run of line tenders rather than a single wave of investment.

Why does the chronic-disease burden keep lines running?

Chronic conditions give factories long, predictable production runs, since patients refill the same molecules every month for years. Local manufacturing covers about 92% to 94% of demand for essential and chronic medicines, Business Monthly reported in August 2026, so most new chronic prescriptions become local output. Insulin shows how the gap is closing, as EVA Pharma launched the first locally made insulin glargine at its Giza factory in December 2024, Al-Ahram reported. Officials said insulin imports had cost USD 30 million by the end of September 2024, and the partners aim to reach more than one million people a year by 2030. Cardiometabolic lines keep the largest share of value, 34.0% in 2025, and give producers a stable base to finance newer sterile capacity.

Download Free Sample

What do WHO recognition and export targets change for makers?

International regulatory recognition turns Egyptian plants into credible suppliers for foreign tenders and registrations. Egypt's drug regulator reached maturity level 3 for medicines in November 2024, after reaching it for vaccines in 2022, making it the first African country with both, according to the World Health Organization. The Egyptian Drug Authority puts 2025 exports at about USD 1.3 billion and targets USD 3 billion by 2030, including USD 1.34 billion to Africa. Africa already took USD 216 million of Egyptian medical exports in 2024, about 26% of the total, the Export Council for Medical Industries says. Reliance on a recognized regulator shortens registration abroad, which favors firms with dossiers ready for African agencies.

Will universal health insurance add institutional demand?

The universal health insurance system widens the institutional market, because each new governorate adds a contracted network of hospitals and clinics that buy medicines centrally. The first phase in six governorates, from Port Said to Aswan, covered about 5.2 million people with an 81.7% registration rate by November 2025, EnterpriseAM reported in August 2026. The second phase in Minya, Matrouh, Damietta, Kafr El Sheikh and North Sinai targets about 12 million to 13 million more people, backed by 69 hospitals and 669 primary care units. France's development agency signed a EUR 150 million policy loan for the program in June 2026. Producers with tender pricing and reliable supply stand to gain volume as the scheme moves toward Cairo and Giza.

Biologics, Gulf plants and finance reshape the industry

Shift from imported biologics toward local sterile protein lines

Producers are moving up the value chain from tablets into sterile biologics, the segment with the highest prices per dose. Minapharm and Bayer signed a localization agreement on Nov. 15, 2025, in the presence of the drug authority chairman, Daily News Egypt reported, and the regulator links such deals to its WHO recognition. EnterpriseAM counted only four biological drug factories in November 2025, which shows how thin this capacity still is. The government also laid the foundation stone of the USD 220 million Genfex vaccine plant in the Suez Canal Economic Zone on Dec. 16, 2025, planned for 70 million to 80 million doses a year at first. Firms that master cell culture and fill-finish can win licensed products that generic rivals cannot copy.

Rise of Egyptian-owned plants in Saudi Arabia and the Gulf

Egyptian producers are building plants inside Gulf markets to meet local-content rules and protect export sales. APEX Pharma started operations at its first plant in King Abdullah Economic City in March 2025, Sharikat Mubasher reported, launching a hypertension medicine approved by the Saudi regulator. Pharco is moving ahead with a SAR 155 million plant in Medina that should start production in 2028, EnterpriseAM reported in May 2026. Marcyrl agreed in October 2026 to localize fertility and respiratory medicines in the UAE with Mubadala Bio, The Source reported. Demand in Saudi Arabia rewards local presence, so Egyptian factories may ship more technology and fewer finished packs to the Gulf over time.

Download Free Sample

Can licensed production for multinationals fill spare capacity?

Licensed and contract production for multinational brand owners is an opening for plants that run below capacity. EnterpriseAM reported in November 2025 that 7 international companies from the United States, China, India and Europe had asked to expand their local production in 2026. Sanofi granted Minapharm exclusive rights to make and supply its anticoagulant Clexane in Egypt, Fierce Pharma reported, while Sanofi's own Cairo plant, running since 1962, makes 120 million units a year. Eli Lilly supplies insulin ingredient at a reduced price and transfers formulation and fill-finish technology to EVA Pharma free of charge, Health Policy Watch reported in May 2023. Each license brings a known brand, a transfer of know-how and assured offtake, which lowers the risk of adding new lines.

Will subsidized credit fund the next round of upgrades?

Cheaper credit can help mid-sized producers upgrade plants that need new lines to stay competitive. An EGP 7 billion financing package offers subsidized interest of 5% to 7% to manufacturers, Al Majalla reported in December 2025. Daily News Egypt reported in May 2025 that only 11 of 170 factories held international accreditation from bodies such as WHO and EMA, which shows how much upgrade work remains. The DG Tresor of France counted 40 more drug factories under construction in August 2025. Suppliers of clean rooms, isolators, inspection systems and validation services stand to gain, because accreditation is the gate to regulated export markets and to multinational license work.

Imported inputs, fixed prices and accreditation gaps

Imported raw materials expose costs to the pound

Dependence on imported inputs leaves factory costs tied to the exchange rate. Egypt imports more than 90% of its pharmaceutical raw materials, the drug authority head said, as EnterpriseAM reported in May 2026, and the dollar passed EGP 56 on Oct. 26, 2026. Every currency move raises the cost of each batch before prices can change. Upstream active ingredient plants in the canal zone will ease this exposure only after they reach full output.

Fixed retail prices lag rising production costs

Mandatory pricing compresses margins whenever costs move faster than approved prices. The last broad repricing came in October 2024, at an exchange rate of EGP 50 to 51 per dollar, EnterpriseAM reported in November 2025. In 2025, hundreds of firms called for price increases across the market, and the drug authority resisted, citing a stronger pound. Producers respond by cutting low-margin presentations, which can cause gaps on pharmacy shelves until new prices are approved.

Smaller factories face a cash squeeze in 2026

Liquidity pressure threatens small and medium producers that depend on distributor credit. Ali Ouf of the federation's pharmaceutical division expects a difficult 2026 for such factories, some of which may exit, EnterpriseAM reported in November 2025. He also warned that the exit of small distributors could remove more than EGP 50 billion of liquidity from the drug circulation cycle. The government had settled 90% of arrears owed to drug companies by May 2026, which eases but does not end the squeeze on weaker firms.

High registration costs slow new product launches

Registration costs raise the bar for launching new generic products in Egypt. The drug authority fee rose to EGP 5 million per product, from EGP 1 million before 2018, EnterpriseAM reported in November 2025. For a mid-sized firm that files dozens of dossiers a year, the fee alone ties up significant capital before any sale. Larger producers absorb it more easily, so the rule favors consolidation and leaves fewer suppliers for low-price molecules that smaller firms used to cover.

Greater Cairo leads while the canal zones grow fastest

Greater Cairo and Giza hosts most large generic plants

Greater Cairo and Giza held 46.0% of 2025 value and grows at 7.5% a year. The region includes 6th of October City, Obour, Badr and the Khanka medicine city, and it hosts EVA Pharma's Giza factory, where the first local insulin was filled. SEDICO opened an EGP 1 billion oncology plant in 6th of October City in March 2023, designed for about 10 million units a year, Zawya reported. Proximity to national distributors and the largest pool of pharmacists keeps new capacity here.

The Sharqia cluster gains biologics capacity

The Sharqia Industrial Cluster held 26.0% of 2025 value and grows at 8.2% a year, centered on 10th of Ramadan City. EIPICO opened its EIPICO 3 plant there in July 2026, an investment of more than USD 100 million designed to make 14 biological products for cancer, blood disorders, infertility and kidney disease, The Middle East Observer reported. EIPICO's three plants together can make about 327 million packages a year. Biologics output makes this cluster the second engine of growth.

Download Free Sample

Alexandria and Borg El Arab specialize in export lines

Alexandria and Borg El Arab held 18.0% of 2025 value and grow at 7.8% a year, anchored by Pharco and port access for exports. Pharco opened an eye drop line of up to 20 million packs a year at its Amreya facility in April 2026, about 19% of domestic demand of more than 100 million packs, according to Daily News Egypt. The port makes this zone a natural base for shipments to Africa and the Gulf.

Canal zones and Upper Egypt grow from a small base

Upper Egypt and other industrial zones held 10.0% of 2025 value and grow fastest at 8.8% a year. Growth comes mainly from Ain Sokhna in the Suez Canal Economic Zone, where ARAB API, an alliance of EIPICO, ACDIMA and the zone authority, plans a USD 120 million plant for 54 active ingredients and 700 to 750 tons a year, The Middle East Observer reported in September 2025. Upper Egypt governorates mostly receive goods from northern plants rather than making them.

Download Free Sample

Plant openings and pricing reform from 2024 to 2026

Sterile, biologic and upstream capabilities set the pace

• Sterile and aseptic filling lets plants make injectables, eye drops and intravenous fluids, the forms where Egyptian capacity is now growing fastest.
• Cell culture and protein purification are the base of biosimilar and insulin production, and only a handful of local plants run them at commercial scale.
• High-containment suites protect workers and products when plants handle potent cancer drugs and hormones, which licensed oncology transfers require.
• Blow-fill-seal technology forms, fills and seals plastic containers in one step, which cuts contamination risk and cost for intravenous solutions.
• Serialization and track-and-trace systems give each pack a unique code that regulators and export buyers increasingly expect before they accept supply.

Egyptian generic leaders compete with multinational plants

Competition in the Egypt pharmaceutical manufacturing market centers on a group of large local generic houses that compete with the Egyptian plants of multinational companies. EVA Pharma and Pharco lead on portfolio breadth and exports, with EVA adding insulin and cancer medicines and Pharco expanding sterile eye care lines in Alexandria. Amoun, owned by Abu Dhabi's ADQ, and EIPICO, half-owned by the Arab Company for Drug Industries and Medical Appliances (ACDIMA), rank among the largest volume producers. Minapharm leads local biologics, SEDICO focuses on oncology transfers, and Marcyrl specializes in hormonal and respiratory products. Rameda runs three factories in 6th of October City, Global Napi adds contract manufacturing of tablets, capsules and injectables, and APEX Pharma opened its first Saudi plant in March 2025. Firms compete on registration speed, tender pricing, multinational licenses and export accreditation rather than on list price, which the state sets.

How concentrated is Egyptian drug production?

Production is split between a group of large Egyptian generic houses, a few state-owned firms under ACDIMA and the holding company, and the local plants of multinationals such as Sanofi, Pfizer, Novartis and Servier. EVA Pharma, Pharco, Amoun, EIPICO and Minapharm compete on portfolio breadth, while toll makers fill spare lines through contract production for license holders, as Minapharm does for Sanofi's Clexane. Entry barriers are moderate for tablets but high for sterile and biologic products, which need costly clean rooms and inspections. Margins are thinnest on price-capped chronic generics and highest on biologics, oncology and export products.

Leading Egyptian drug producers and their roles

Credence Research view on value-added drug production

Credence Research's view is that the Egypt pharmaceutical manufacturing market has largely finished its first task of covering domestic volume, and it now competes on value. Local factories meet about 92% of demand by volume and 85% by value, so new growth must come from biologics, oncology, sterile products and exports. Pricing reform that ties approved prices to costs and favors local products improves the investment case, but only if repricing keeps pace with the currency. Buyers and investors should watch the first reviews under the new formula, the start-up of the canal zone ingredient plants and the pace of African registrations.

Sales, trade and plant data anchor the estimate

The report uses 2025 as the base year and 2026 to 2035 as the forecast period. Market values come from the Credence Research model, checked against Egyptian Drug Authority sales data, UN Comtrade trade data, export council statements and industry estimates of local production shares. Product type, dosage form, therapeutic area, customer type and regional splits are Credence Research estimates. Inputs include regulator and WHO releases, company announcements, development bank releases and press reports that name their sources. No interviews or surveys were used in preparing these estimates.

Biologics, oncology and exports gain share to 2035

The Egypt pharmaceutical manufacturing market is expected to reach USD 10.76 billion by 2035, growing at 7.92% a year during 2026–2035. Greater Cairo and Giza stays the largest production region, while the canal zones and Upper Egypt grow fastest as ingredient, vaccine and fluid plants open. Generics keep the largest share, but biologics and biosimilars gain, and oncology and hematology medicines grow at 9.8% a year as licensed transfers and new sterile lines come on stream. Export buyers become the fastest-growing customer group at 9.6% a year if African registrations speed up. A stable pound and timely repricing would lift this outlook, while renewed currency weakness would hold it back.

Currency stability and pricing decide the range of outcomes

The range of outcomes depends mainly on how stable the pound remains and whether the new pricing formula lets factories pass on cost increases on time. A downside follows if the currency weakens again, active ingredient imports stay at current levels and approved prices lag for another two years. An upside needs the canal zone ingredient and vaccine plants to reach full output, biologics licenses to multiply and African registrations to speed up under the WHO recognition. The base case assumes gradual repricing, steady localization and moderate growth in exports to Africa.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.